MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$50.12M, compared with -$43.76M a year earlier.
Context
- Net debt amounted to 12.0% of total assets at the end of Q1 FY2026, down 27.3 pp from a year earlier.
- Net debt grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -14.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (40.93M) USD
- Year-over-year change
- -29.2%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (40.93M) | -29.2% |
| FY2024 | 2024-12-31 | (31.67M) | +57.1% |
| FY2023 | 2023-12-31 | (73.85M) | -245.2% |
| FY2022 | 2022-12-31 | (21.39M) | — |
Net Debt vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 net debt of -$50.12M is the highest of the 11 companies compared; the peer median is -$175.58M.
- Its year-over-year change of -14.5% is the 3rd highest of 11, against a peer median of -288.8%.
- Net debt amounts to 12.0% of total assets for MPLT, versus a peer median of 60.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$50.12M | -14.5% | — | 12.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | -$67.25M | -35.1% | — | 13.5% |
| Mar 2026 | -$92.61M | -1280.9% | — | 41.0% | |
| Mar 2026 | -$94.45M | -485.5% | — | 33.9% | |
| Dec 2025 | -$131.75M | -9.1% | — | 99.1% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | -$146.66M | -16.5% | — | 95.3% |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | -$204.49M | -1101.1% | — | 19.0% |
| Mar 2026 | -$242.22M | +0.8% | — | 88.0% | |
| Mar 2026 | -$258.07M | -92.1% | — | 93.4% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | -$317.21M | -2931.4% | — | 80.6% |
| Jun 2026 | -$24.58B | -161104.7% | — | 25.8% | |
| Peer median (excluding MPLT) | -$175.58M | -288.8% | — | 60.8% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.